These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36939675)

  • 1. A Novel Fc-Engineered Anti-HER2 Bispecific Antibody With Enhanced Antitumor Activity.
    Mohammadi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Arjmand M; Torkashvand F; Bahadori T; Judaki MA; Shiravi F; Ahmadi Zare H; Notash Haghighat F; Mobini M; Shokri F; Amiri MM
    J Immunother; 2023 May; 46(4):121-131. PubMed ID: 36939675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects
    Mohammadi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Arjmand M; Bahadori T; Judaki MA; Shiravi F; Zare HA; Haghighat FN; Mobini M; Amiri MM; Shokri F
    Front Immunol; 2020; 11():600883. PubMed ID: 33679691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models.
    Shiravi F; Mohammadi M; Golsaz-Shirazi F; Bahadori T; Judaki MA; Fatemi F; Zare HA; Haghighat FN; Mobini M; Jeddi-Tehrani M; Amiri MM; Shokri F
    Invest New Drugs; 2021 Jun; 39(3):697-704. PubMed ID: 33389387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
    Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
    Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
    Zhang N; Liu L; Dumitru CD; Cummings NR; Cukan M; Jiang Y; Li Y; Li F; Mitchell T; Mallem MR; Ou Y; Patel RN; Vo K; Wang H; Burnina I; Choi BK; Huber HE; Stadheim TA; Zha D
    MAbs; 2011; 3(3):289-98. PubMed ID: 21487242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
    Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.
    Amiri MM; Golsaz-Shirazi F; Soltantoyeh T; Hosseini-Ghatar R; Bahadori T; Khoshnoodi J; Navabi SS; Farid S; Karimi-Jafari MH; Jeddi-Tehrani M; Shokri F
    Invest New Drugs; 2018 Apr; 36(2):171-186. PubMed ID: 28983766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
    Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
    Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
    Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
    Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3.
    Rau A; Kocher K; Rommel M; Kühl L; Albrecht M; Gotthard H; Aschmoneit N; Noll B; Olayioye MA; Kontermann RE; Seifert O
    MAbs; 2021; 13(1):1902034. PubMed ID: 33752566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.
    Turini M; Chames P; Bruhns P; Baty D; Kerfelec B
    Oncotarget; 2014 Jul; 5(14):5304-19. PubMed ID: 24979648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo.
    Wang Z; Liu Y; Xu Y; Lu L; Zhu Z; Lv B; Fang X; Tang Y; Wang J; Cheng Y; Hu Y; Lou J; Wu P; Liu C; Liu Y; Zeng X; Xu Q
    MAbs; 2024; 16(1):2412881. PubMed ID: 39381966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.
    Pedersen MW; Jacobsen HJ; Koefoed K; Dahlman A; Kjær I; Poulsen TT; Meijer PJ; Nielsen LS; Horak ID; Lantto J; Kragh M
    Mol Cancer Ther; 2015 Mar; 14(3):669-80. PubMed ID: 25612619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy.
    Chen YL; Cui Y; Liu X; Liu G; Dong X; Tang L; Hung Y; Wang C; Feng MQ
    J Biol Chem; 2021 Dec; 297(6):101420. PubMed ID: 34798072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
    Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
    Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.